The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc. using a superconducting quantum interference device (SQUID)-based magnetometers is being used for heart screenings and may be able to quickly detect myocarditis in COVID-19 patients without any physical contact. The medical device called Avalon-H90.
COVID-19 causes myocarditis in many of those infected. So, there is a need for fast, noninvasive and reliable heart screening for all patients who were affected by COVID-19 and potentially developed myocarditis.
According to the article published by Ohio State University Sept. 11, 2020 in medical journal JAMA, 26 competitive athletes who had COVID-19 had symptoms of myocarditis.[1] Myocarditis affects the heart muscle and can cause heart failure or sudden death. Steven Erickson, M.D., a sports medicine specialist at Banner — University Medical Center in Phoenix, Ariz., told USA Today that athletes should be symptom-free for two weeks before getting back into the game.
Although widely used as a screening tool, the sensitivity of electrocardiogram (ECG) for myocarditis is only less than 50 percent and is very non-specific. The most common ECG findings are non-specific T-wave changes.
The Mesuron team believes its technology is most sensitive to detect any T-wave changes. It is fast, non-invasive, no injection, no radiation, no contact, high sensitivity at rest detection of ventricular myocardial repolarization abnormalities, that reflects several myocardial problems, including ischemia.
Mesuron Inc. has developed Ventricular Repolarization Dynamics Analysis (VRDA) on the Avalon-H90 that detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential (EAP) of normal heart tissues and abnormal ones with hypoxia. The vendor says is also robust enough to detect abnormalities without hypoxia due to changes in muscle chemistry related to insufficient blood supply or other myocardial abnormalities.
Avalon-H90 takes approximately 5 minutes to deliver test results that can separate high and low risk cardiac patients and help the physician make early decisions.
Avalon-H90 is a fully developed prototype. It is designed for use in hospitals' emergency departments and outpatient clinics. The company is looking for partnerships to conduct a medical trial for detecting myocardial abnormalities in acute chest pain (ACP) patients. One trial has already been arranged with Mayo Clinic.
For more information: www.mesuron.com
Read more about this technology being developed by another start up company:
Key Technology and News at AHA 2018
VIDEO: Editor's Choice of the Most Innovative New Cardiac Technology at AHA 2018
Reference:
January 23, 2024 
